TherapeuticDrug Monitoring (TDM) has an important role in the management of inflammatorybowel disease (IBD) patients on infliximab (IFX) or adalimumab and isrecommended in IBD patients presenting a loss of response under anti TNF agent.But, TDM was not recommended for others biotherapies. Analyzing all publications about TDM and biologics in IBD patients, we reportedthe major results for each biotherapy. emerging data suggest that TDM will probably be similarly useful forIFX SC. In contrast, there is no demonstrated clinical benefit to the use ofTDM with golimumab. For vedolizumab results for the use of both reactive andproactive TDM are discordant. For ustekinumab, data supports the existence ofan exposure response relationship, albeit of a lesser magnitude than withanti-TNF agents. Finally, recent data from small case series suggests that TDMcould be valuable in optimizing anti-IL23 agents, particularly risankizumab,but this requires further clarification. Consistent with the new concept of'preactive' strategy, recent data support the utility of dashboard-driven modelinformed precision dosing (MIDP) of anti-TNF agents, in particular infliximab.Dashboards are software systems using Bayesian population pharmacokineticmodelling to individualize recommendations for target drug levels.